Mayne Pharma Group Ltd
ASX:MYX
Intrinsic Value
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. [ Read More ]
The intrinsic value of one MYX stock under the Base Case scenario is 7.56 AUD. Compared to the current market price of 7.24 AUD, Mayne Pharma Group Ltd is Undervalued by 4%.
Valuation Backtest
Mayne Pharma Group Ltd
Run backtest to discover the historical profit from buying and selling MYX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Mayne Pharma Group Ltd
Current Assets | 475.3m |
Cash & Short-Term Investments | 154.8m |
Receivables | 198.9m |
Other Current Assets | 121.6m |
Non-Current Assets | 677.3m |
PP&E | 50.4m |
Intangibles | 584.6m |
Other Non-Current Assets | 42.4m |
Current Liabilities | 295.7m |
Accounts Payable | 42.8m |
Accrued Liabilities | 180.1m |
Other Current Liabilities | 72.8m |
Non-Current Liabilities | 309.2m |
Long-Term Debt | 33.1m |
Other Non-Current Liabilities | 276.1m |
Earnings Waterfall
Mayne Pharma Group Ltd
Revenue
|
278.4m
AUD
|
Cost of Revenue
|
-89m
AUD
|
Gross Profit
|
189.5m
AUD
|
Operating Expenses
|
-286.9m
AUD
|
Operating Income
|
-97.4m
AUD
|
Other Expenses
|
-145.9m
AUD
|
Net Income
|
-243.3m
AUD
|
Free Cash Flow Analysis
Mayne Pharma Group Ltd
What is Free Cash Flow?
MYX Profitability Score
Profitability Due Diligence
Mayne Pharma Group Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Mayne Pharma Group Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
MYX Solvency Score
Solvency Due Diligence
Mayne Pharma Group Ltd's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Score
Mayne Pharma Group Ltd's solvency score is 57/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MYX Price Targets Summary
Mayne Pharma Group Ltd
According to Wall Street analysts, the average 1-year price target for MYX is 7.18 AUD with a low forecast of 6.76 AUD and a high forecast of 7.75 AUD.
Shareholder Return
MYX Price
Mayne Pharma Group Ltd
Average Annual Return | -25.33% |
Standard Deviation of Annual Returns | 10.3% |
Max Drawdown | -79% |
Market Capitalization | 588.2m AUD |
Shares Outstanding | 85 074 304 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
Contact
IPO
Employees
Officers
The intrinsic value of one MYX stock under the Base Case scenario is 7.56 AUD.
Compared to the current market price of 7.24 AUD, Mayne Pharma Group Ltd is Undervalued by 4%.